HomeHome
ProductsProducts
Bioactive CompoundsBioactive Compounds
Protein Kinase TargetsProtein Kinase Targets
BTKBTK
ZanubrutinibZanubrutinib

Zanubrutinib

CAS No.	1691249-45-2
MDL No.	N/A
MF	C₂₇H₂₉N₅O₃
MW	471.50
InChI Key	RNOAOAWBMHREKO-QFIPXVFZSA-N

CUSTOM SYNTHESIS

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1691249-45-2
Product Name	Zanubrutinib

Health Hazard

Signal Word:Danger

HCode:H360

PCode:P203-P280-P318-P405-P501

Studies related to this compound and its mechanism of action

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.

Haematologica • Vol. 106, Issue 9 • 2021

PMID: 33054121 PMC: PMC8409041 DOI: 10.3324/haematol.2020.259432

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020

PMID: 32020584 PMC: PMC7160657 DOI: 10.1111/imm.13175

The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Hematological oncology • Vol. 37, Issue 4 • 2019

PMID: 31420873 DOI: 10.1002/hon.2667

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Journal of medicinal chemistry • Vol. 62, Issue 17 • 2019

PMID: 31381333 DOI: 10.1021/acs.jmedchem.9b00687

Similar Products

((plusmn))-Zanubrutinib
CAS No.1633350-06-7

Products
- CDMO Compounds
- API & Candidates
Services
CDMO & Manufacturing
Custom Synthesis
Process Development
Lab To Pilot
Commercialization
Generic APIs
CRO
Preclinical
Pharmacology & Efficacy
DMPK & Bioanalysis
Toxicology & Safety
Disease Models
Technologies
High-Potent
Chiral Synthesis
Cloud Synthesis
Fermentation
Flow Chemistry
Biocatalysis
Support
Regulatory Support
Supply Chain Solutions
About
Perspectives
Contact

HomeHome
ProductsProducts
Bioactive CompoundsBioactive Compounds
Protein Kinase TargetsProtein Kinase Targets
BTKBTK
ZanubrutinibZanubrutinib

Zanubrutinib

CAS No.	1691249-45-2
MDL No.	N/A
MF	C₂₇H₂₉N₅O₃
MW	471.50
InChI Key	RNOAOAWBMHREKO-QFIPXVFZSA-N

CUSTOM SYNTHESIS

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1691249-45-2
Product Name	Zanubrutinib

Health Hazard

Signal Word:Danger

HCode:H360

PCode:P203-P280-P318-P405-P501

Studies related to this compound and its mechanism of action

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.

Haematologica • Vol. 106, Issue 9 • 2021

PMID: 33054121 PMC: PMC8409041 DOI: 10.3324/haematol.2020.259432

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020

PMID: 32020584 PMC: PMC7160657 DOI: 10.1111/imm.13175

The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Hematological oncology • Vol. 37, Issue 4 • 2019

PMID: 31420873 DOI: 10.1002/hon.2667

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Journal of medicinal chemistry • Vol. 62, Issue 17 • 2019

PMID: 31381333 DOI: 10.1021/acs.jmedchem.9b00687

Similar Products

((plusmn))-Zanubrutinib
CAS No.1633350-06-7

Your Partner for
Complex Chemistry

About Us
Perspectives
Products
Contact

Preclinical Development
Technologies
Custom Synthesis

Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT

Westerstraat 10, 3016 DH, Rotterdam, The Netherlands

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|

Zanubrutinib

Pricing & Availability

Product Information

Safety Information

Properties

Zanubrutinib

Pricing & Availability

Product Information

Safety Information

Properties

Documentation

Zanubrutinib

Pricing & Availability

Product Information

Safety Information

Properties

Related Articles

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Similar Products

((plusmn))-Zanubrutinib

Zanubrutinib

Pricing & Availability

Product Information

Safety Information

Properties

Related Articles

Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Similar Products

((plusmn))-Zanubrutinib

Documentation